Pfizer-BioNTech COVID-19 Vaccine was authorized on December 9, 2020, for use in accordance with the
Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Since the time of authorization, Pfizer-BioNTech has submitted data to Health Canada to support alternative temperature for transportation and storage conditions.
Products affected
Pfizer-BioNTech COVID-19 Vaccine, suspension for intramuscular injection, multiple dose vials. After dilution, the vial contains 6 doses (each dose is 0.3 mL).
DIN: 02509210
Manufacturer: BioNTech Manufacturing GmbH (Germany)
Canadian Importer and Distributor: Pfizer Canada ULC
Background information
Pfizer-BioNTech COVID-19 Vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.
At the time of authorization, the Pfizer-BioNTech COVID-19 Vaccine Product Monograph (PM) and vial and carton labels indicated that prior to use, the vaccine should only be stored/transported in an ultra-low temperature freezer between -80°C to -60°C. Based on updated information, vials may also be stored/transported at -25°C to -15°C for a period of
up to 2 weeks. Vials must be kept frozen and protected from light, in the original cartons, until ready to use. Vials stored/transported at -25°C to -15°C for
up to 2 weeks may be returned
once to the recommended storage condition of -80°C to -60°C.
In addition, available updated data support transportation of thawed undiluted vials at 2°C to 8°C for
up to 12 hours. Thawed undiluted vials should be stored at 2°C to 8°C for no more than 120 hours (5 days).
Any hours used for transport at 2°C to 8°C count against the 120-hour limit for storage at 2°C to 8°C.
Health Canada has authorized updates to the Pfizer-BioNTech COVID-19 Vaccine PM to reflect the new information.